436 related articles for article (PubMed ID: 16117149)
1. [Interferons beta in patients with multiple sclerosis].
Vlasov IaV; Kuznetsova NI; Poverennova IE; Khivintseva EV
Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(7):54-5. PubMed ID: 16117149
[No Abstract] [Full Text] [Related]
2. Widespread urticaria due to intramuscular interferon beta-1a therapy for multiple sclerosis.
Guijarro C; Benito-León J; Bermejo-Pareja F
Neurol Sci; 2011 Apr; 32(2):309-11. PubMed ID: 20890624
[TBL] [Abstract][Full Text] [Related]
3. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.
Tremlett HL; Oger J
Neurology; 2003 Aug; 61(4):551-4. PubMed ID: 12939437
[TBL] [Abstract][Full Text] [Related]
4. Gender effects on intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis: analysis of 1406 patients.
Rudick RA; Kappos L; Kinkel R; Clanet M; Phillips JT; Herndon RM; Sandrock AW; Munschauer FE
Mult Scler; 2011 Mar; 17(3):353-60. PubMed ID: 20965959
[TBL] [Abstract][Full Text] [Related]
5. [The comparative study of efficacy and tolerability of intramuscular introduction of beta-interferon-1a in adults and adolescents with remitting multiple sclerosis].
Boĭko AN; Batysheva TT; Bykova OV; Davydovskaia MV; Demina TL; Lashch NIu; Nankina IA; Ovcharov VV; Popova EV; Popova NF; Boĭko OV; Khachanova NV; Shchur SG; Gusev EI
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(2 Pt 2):98-103. PubMed ID: 22677685
[TBL] [Abstract][Full Text] [Related]
6. [PRISMS study. Interferon beta-1a therapy in relapsing-remitting multiple sclerosis].
Limmroth V
Internist (Berl); 2001 Feb; 42(2):305-7. PubMed ID: 11244885
[No Abstract] [Full Text] [Related]
7. Subcutaneous recombinant interferon-beta-1a (Rebif): a review of its use in relapsing-remitting multiple sclerosis.
Murdoch D; Lyseng-Williamson KA
Drugs; 2005; 65(9):1295-312. PubMed ID: 15916455
[TBL] [Abstract][Full Text] [Related]
8. [Interferon therapy of multiple sclerosis].
Jensen D
Tidsskr Nor Laegeforen; 1999 Sep; 119(21):3142-5. PubMed ID: 10522481
[TBL] [Abstract][Full Text] [Related]
9. Depression in multiple sclerosis associated with interferon beta-1a (Rebif).
Pandya R; Patten S
Can J Psychiatry; 2002 Sep; 47(7):686. PubMed ID: 12355685
[No Abstract] [Full Text] [Related]
10. Autoimmune hepatitis-like reaction developing in a patient treated with interferon-β1a.
Mishra A; Guindi M; Kandel G; Streutker CJ
Histopathology; 2015 Mar; 66(4):605-7. PubMed ID: 24796493
[No Abstract] [Full Text] [Related]
11. Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy.
Trojano M; Liguori M; Paolicelli D; Zimatore GB; De Robertis F; Avolio C; Giuliani F; Fuiani A; Livrea P;
Mult Scler; 2003 Oct; 9(5):451-7. PubMed ID: 14582768
[TBL] [Abstract][Full Text] [Related]
12. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre.
Río J; Tintoré M; Nos C; Téllez N; Galán I; Montalban X
J Neurol; 2005 Jul; 252(7):795-800. PubMed ID: 15772741
[TBL] [Abstract][Full Text] [Related]
13. [The use of rebif in the Moscow Municipal Multiple Sclerosis Center].
Popova EV; Boĭko AN; Davydovskaia MF; Demina TL; Lashch NIu; Popova NF; Khachanova NV; Shchur SG; Gusev EI
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):68-71. PubMed ID: 21916159
[TBL] [Abstract][Full Text] [Related]
14. The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.
Durelli L; Barbero P; Bergui M; Versino E; Bassano MA; Verdun E; Ferrero B; Rivoiro C; Ferrero C; Picco E; Ripellino P; Viglietti D; Giuliani G; Montanari E; Clerico M;
J Neurol; 2008 Sep; 255(9):1315-23. PubMed ID: 18825438
[TBL] [Abstract][Full Text] [Related]
15. Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study.
Singer B; Bandari D; Cascione M; LaGanke C; Huddlestone J; Bennett R; Dangond F;
BMC Neurol; 2012 Dec; 12():154. PubMed ID: 23216674
[TBL] [Abstract][Full Text] [Related]
16. Improving the convenience of home-based interferon beta-1a therapy for multiple sclerosis.
Lesaux J; Jadbäck G; Harraghy CE
J Neurosci Nurs; 1999 Jun; 31(3):174-9. PubMed ID: 10846648
[TBL] [Abstract][Full Text] [Related]
17. The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis. The Danish Multiple Sclerosis Group.
Koch-Henriksen N; Sørensen PS
Mult Scler; 2000 Jun; 6(3):172-5. PubMed ID: 10871828
[TBL] [Abstract][Full Text] [Related]
18. Spotlight on subcutaneous recombinant interferon-beta-1a (Rebif) in relapsing-remitting multiple sclerosis.
Murdoch D; Lyseng-Williamson KA
BioDrugs; 2005; 19(5):323-5. PubMed ID: 16207073
[TBL] [Abstract][Full Text] [Related]
19. Widespread maculopapular rash due to intramuscular interferon beta-1a during the treatment of multiple sclerosis.
Serarslan G; Okuyucu E; Melek I; Hakverdi S; Duman T
Mult Scler; 2008 Mar; 14(2):259-61. PubMed ID: 18337427
[TBL] [Abstract][Full Text] [Related]
20. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]